Cancer Diagnostics Market

Cancer Diagnostics Market: Biopsy Test Type Segment Expected to Remain Dominant Throughout the Forecast Period: Global Industry Analysis and Opportunity Assessment 2016 - 2026

Biopsy is expected to remain the most lucrative cancer diagnostics test due to technological advancements such as fine needle aspiration

The biopsy test type segment dominated the global cancer diagnostics market in revenue terms in 2016, and the trend is projected to continue throughout the forecast period. Biopsy is the largest segment, which was valued at more than US$ 11 Bn in 2016 and is expected to expand at a CAGR of 7.4% over the forecast period. The liquid biopsy test type segment is expected to register fastest Y-o-Y growth throughout the forecast period. Even though liquid biopsy is becoming more popular due to its non-invasive nature, to obtain an accurate diagnosis, solid tumour biopsies or tissue biopsies are still preferred.

Despite the headwinds of regulatory uncertainties, diagnostic companies continue to invest in high dollar molecular diagnostic tests for cancer research

To purchase test reagents, a majority of diagnostic companies place these instruments in diagnostic and research laboratories through reagent rental contracts in exchange for long-term contracts, as tests can only be run in laboratories possessing instruments for which the test is developed and approved. Moreover, newly developed tests for particular instruments need to be mass marketed to diagnostic laboratories, general practitioners, and health insurers. For instance, big players such as Roche Diagnostics, Abbott etc. license their cancer test products to regional geographical partners who either distribute these products in the region or develop reagent kits for their instruments. Addressing the huge needs in cancer diagnostics require the participation of established diagnostics industry players.

Changing competition landscape is the new trend that can be seen in the global cancer diagnostics market. Although molecular testing is a hotspot for investment in vitro diagnostic, the market shows delayed growth due to slow returns on investment. In spite of this, all big diagnostic players in the global market are continuously investing in cancer diagnostics including molecular biomarker testing, NGS, PET scanners etc. Companies are also investing in automation of existing molecular assays to foster future growth prospects. The majority of cancer diagnostic players are adopting inorganic growth strategies to sustain the increasing competitive pressure. Companies in the global market are actively engaged in mergers and acquisitions, as the industry is in its growth phase because of continuous technology upgrades and launch of novel blood tests to detect cancer. Key players in the liquid biopsy industry have started taking strategic decisions to engage in mergers and acquisitions to strengthen their product portfolio and increase their brand share in the market.

Change in regulatory policies is reflecting in the change of approach towards cancer diagnostics. Due to automation of laboratory testing methods, traditional methods have been replaced by high-volume models and tests have become commoditised.

Regional forecast of the test type segment

The biopsy test type segment dominated the North America cancer diagnostics market in terms of revenue in 2015 and is projected to continue to do so throughout the forecast period. Biopsy is expected to be the most lucrative segment in the North America cancer diagnostics market, with a market attractiveness index of 2.9. Steady advances in the field of bone marrow biopsy in the last few years have facilitated the accurate diagnosis of complex indications such as Hodgkin's lymphoma, lymphoplasmacytic lymphoma and other cancers of lymph and vascular systems. The biopsy segment is expected to be the most lucrative test type segment in the Western Europe cancer diagnostics market, with a market attractiveness index of 3.2. New developments in fine needle aspiration tools for diagnosis of different cancer indications including lung cancers, head and neck cancers and advanced breast cancer among others has led to an increased demand for tissue biopsy. Further, majority of lung cancers are diagnosed at a late stage where fine needle aspiration biopsy is the only possible test done to confirm the presence of cancer.

The analysts of Future Market Insights have focussed on various segments of the global cancer diagnostics market and have observed that hospital-associated laboratories accounted for the highest market share in 2015 and are likely to remain dominant during the next decade. Independent diagnostics laboratories would represent fastest growth opportunities due to increasing demand for diagnostics imaging. The analysts have also covered the various regions while inspecting the global cancer diagnostics market and have observed that North America represents the most lucrative market, followed by Europe and APAC. It has been noted that the Asia Pacific region holds highest growth opportunity due to increasing spending on cancer diagnosis and treatment, especially in China and India.

In a new report titled “Cancer Diagnostics Market: Global Industry Analysis and Opportunity Assessment 2016–2026,” our analysts have considered important developments in the global cancer diagnostics market such as the rapid pace of cancer research and continuous product approvals for cancer diagnostics, which is projected to drive the growth of the global cancer diagnostics market. Furthermore, lung cancer diagnostics is anticipated to be a highly opportunistic segment for revenue generation due to the substantial increase in lung cancer cases in all parts of the globe. The report also highlights the key growth strategies such as collaborations and mergers and acquisitions adopted by the leading players operating in the global cancer diagnostics market.

Research Methodology

Macro-economic indicators such as healthcare industry outlook, healthcare spending and Gross Domestic Product have been considered to arrive at the indicated market numbers. We have not considered the yearly change in inflation rate while forecasting market numbers. Bottom-up approach has been used to assess market numbers, while top-down approach has been used to counter-validate the market estimations. Our analysts have performed systematic and exhaustive secondary research to analyse the required data points to arrive at the overall market numbers. Future Market Insights has developed extensive questionnaires for each node in the value chain to extract the required market information through key stakeholder interviews. Data thus acquired is then validated using the triangulation method, wherein secondary and primary research and Future Market Insights analysis contributes to the final data interpretation.

Porter’s Analysis – An important component of our research methodology

Porter’s Analysis forms an important part of our research on the global cancer diagnostics market. Some of our findings based on Porter’s Analysis are as follows –

  • Top players in the global cancer diagnostics industry manufacture their own products

  • Leading industry players have minimised the extent of buyer power by creating high switching costs for their customers

  • Lack of effective, specific and sensitive cancer diagnostics implies absolutely no threat of substitutes

  • Government funding to universities and research institutes prevents windfall profits for private players

  • One of the key attributes of the cancer diagnostics industry is that it creates a favourable environment for competitors as there are a number of unique customer segments within the industry that demand a particular type of product

  • Next generation cancer diagnostics will use patented technologies

  • Multiple pathways are currently being targeted so competition will increase in future 

Report Structure

We have provided our clients with primary verbatim inputs from key industry stakeholders so it is easy for them to get a clear picture of how the process of cancer biomarker development is responsible for a gap between biomarker discovery studies and their clinical translation. We have also provided detailed information about cancer epidemiology in various regions and our research indicates that the MEA region has the highest cancer mortality rate due to delayed diagnosis and treatment owing to lack of resources. We have also included the key industry developments from 1903 to 2008 in our report to present a clear picture of the development of the global cancer diagnostics market over the said period of time. The cancer diagnostics regulatory and reimbursement scenario has also been covered in this report, which is categorised into five levels – basic research, prototype design or discovery, preclinical development, clinical development Phase I, II and III and finally FDA filing/approval and launch preparation.

Global Cancer Diagnostics Market – Segmentation

By Test Type

By End User

By Indication

By Region

  • Tumour Biomarkers Tests

    • PSA Tests

    • CTC Tests

    • AFP Tests

    • CA-19 Tests

    • HER2 Tests

    • BRCA Tests

    • ALK Tests

    • CEA Tests

    • EGFR Mutation Tests

    • KRAS Mutation Tests

    • Others

  • Imaging

    • Ultrasound

    • Mammography

    • MRI Scan

    • PET Scan

    • CT Scan

    • SPECT & Others

  • Biopsy

    • Needle Biopsy

    • Endoscopic Biopsy

    • Bone Marrow Biopsy

    • Others

  • Liquid Biopsy

  • Immunohistochemistry

  • In Situ Hybridisation

  • Hospital Associated Labs

  • Independent Diagnostic Laboratories

  • Diagnostic Imaging Centres

  • Cancer Research Institutes

  • Others

  • Breast Cancer

  • Lung Cancer

  • Colorectal Cancer

  • Melanoma

  • Blood Cancer

  • Prostate Cancer

  • Ovarian Cancer

  • Stomach Cancer

  • Liver Cancer

  • Others

  • North America

  • Latin America

  • Western Europe

  • Eastern Europe

  • APEJ

  • Japan

  • MEA 

Table Of Content

1.Executive Summary

2. Market Introduction

2.1.Market Definition

2.2. Market Taxonomy

3. Global Cancer Diagnostics Market Analysis Scenario

3.1.Market Size (US$ Mn) and Forecast

3.1.1.Market Size and Y-o-Y Growth

3.1.2.Absolute $ Opportunity

4. Market Dynamics

4.1.Macro-economic Factors

4.2. Drivers

4.2.1.Supply Side

4.2.2.Demand Side

4.3.Restraints

4.4.Opportunity

4.5.Forecast Factors – Relevance and Impact

4.6.Key Industry Developments

4.7.Cancer Epidemiology, By Region

4.8.Cancer Diagnostics Regulatory and Reimbursement Scenario

4.9.Porter’s Analysis 

4.10.Next-generation Sequencing: A Breakthrough in Cancer Diagnostics

5.Global Cancer Diagnostics Market Analysis and Forecasts, By Test Type 

5.1.Introduction

5.2.Basis Point Share (BPS) Analysis By Test Type

5.3.Y-o-Y Growth Projections By Test Type

5.4.Market Value Forecast By Test, 2016–2026

5.4.1. Tumor Biomarkers Tests

5.4.1.1.PSA Tests

5.4.1.2.CTC Tests

5.4.1.3.AFP Tests

5.4.1.4.CA-19 Tests

5.4.1.5.HER2 Tests

5.4.1.6.BRCA Tests

5.4.1.7.ALK Tests

5.4.1.8.CEA Tests

5.4.1.9.EGFR Mutation Tests

5.4.1.10.KRAS Mutation Tests

5.4.1.11.Others

5.4.2.Imaging

5.4.2.1.Ultrasound

5.4.2.2.Mammography

5.4.2.3.MRI Scan

5.4.2.4.PET Scan

5.4.2.5.CT Scan

5.4.2.6.SPECT & Others

5.4.3.Biopsy

5.4.3.1.Needle Biopsy

5.4.3.2.Endoscopic Biopsy

5.4.3.3.Bone Marrow Biopsy

5.4.3.4.Others

5.4.4.Liquid Biopsy

5.4.5.Immunohistochemistry

5.4.6.In Situ Hybridization

5.5.Market Attractiveness Analysis By Test Type

6.Global Cancer Diagnostics Market Analysis and Forecasts, By End User 

6.1.Introduction

6.2.Basis Point Share (BPS) Analysis By End User 

6.3.Y-o-Y Growth Projections By End User 

6.4.Market Value Forecast By End User, 2016–2026

6.4.1.Hospital Associated Labs

6.4.2.Independent Diagnostic Laboratories

6.4.3.Diagnostic Imaging Centers

6.4.4.Cancer Research Institutes

6.4.5.Others

6.5.Market Attractiveness Analysis By End User 

7.Global Cancer Diagnostics Market Analysis and Forecasts, By Indication 

7.1.Introduction

7.2.Basis Point Share (BPS) Analysis By Indication 

7.3.Y-o-Y Growth Projections By Indication 

7.4.Market Value Forecast By Indication, 2016–2026

7.4.1.Breast Cancer

7.4.2.Lung Cancer

7.4.3.Colorectal Cancer

7.4.4.Melanoma

7.4.5.Blood Cancers

7.4.6.Prostate Cancer

7.4.7.Ovarian Cancer

7.4.8.Stomach Cancer

7.4.9.Liver Cancer

7.4.10.Others

7.5.Market Attractiveness Analysis By Indication 

8.Global Cancer Diagnostics Market Analysis and Forecasts, By Region

8.1.Basis Point Share (BPS) Analysis By Region

8.2.Y-o-Y Growth Projections By Region

8.3.Market Value Forecast By Region

8.3.1.North America 

8.3.2.Latin America 

8.3.3.Western Europe 

8.3.4.Eastern Europe 

8.3.5.APEJ 

8.3.6.Japan 

8.3.7.MEA 

8.4.Market Attractiveness Analysis By Region

9.North America Cancer Diagnostics Market Analysis and Forecast

9.1.Introduction

9.1.1.Basis Point Share (BPS) Analysis By Country

9.1.2.Y-o-Y Growth Projections By Country

9.2.Market Value Forecast By Test, 2016–2026

9.2.1.Tumor Biomarkers Tests

9.2.1.1.PSA Tests

9.2.1.2.CTC Tests

9.2.1.3.AFP Tests

9.2.1.4.CA-19 Tests

9.2.1.5.HER2 Tests

9.2.1.6.BRCA Tests

9.2.1.7.ALK Tests

9.2.1.8.CEA Tests

9.2.1.9.EGFR Mutation Tests

9.2.1.10.KRAS Mutation Tests

9.2.1.11.Others

9.2.2.Imaging

9.2.2.1.Ultrasound

9.2.2.2.Mammography

9.2.2.3.MRI Scan

9.2.2.4.PET Scan

9.2.2.5.CT Scan

9.2.2.6.SPECT & Others

9.2.3.Biopsy

9.2.3.1.Needle Biopsy

9.2.3.2.Endoscopic Biopsy

9.2.3.3.Bone Marrow Biopsy

9.2.3.4.Others

9.2.4.Liquid Biopsy

9.2.5.Immunohistochemistry

9.2.6.In Situ Hybridization

9.3.Market Value Forecast By End User, 2016–2026

9.3.1.Hospital Associated Labs

9.3.2.Independent Diagnostic Laboratories

9.3.3.Diagnostic Imaging Centers

9.3.4.Cancer Research Institutes

9.3.5.Others

9.4.Market Value Forecast By Indication, 2016–2026

9.4.1.Breast Cancer

9.4.2.Lung Cancer

9.4.3.Colorectal Cancer

9.4.4.Melanoma

9.4.5.Blood Cancers

9.4.6.Prostate Cancer

9.4.7.Ovarian Cancer

9.4.8.Stomach Cancer

9.4.9.Liver Cancer

9.4.10. Others

9.5. Market Value Forecast By Country, 2016–2026

9.5.1.U.S.

9.5.2.Canada

9.6.Market Attractiveness Analysis 

9.6.1.By Test 

9.6.2.By End User 

9.6.3.By Indication 

9.6.4.By Country

9.7.Drivers and Restraints: Impact Analysis 

10.Latin America Cancer Diagnostics Market Analysis and Forecast

10.1.Introduction

10.1.1.Basis Point Share (BPS) Analysis By Country

10.1.2.Y-o-Y Growth Projections By Country

10.2.Market Value Forecast By Test, 2016–2026

10.2.1.Tumor Biomarkers Tests

10.2.1.1.PSA Tests

10.2.1.2.CTC Tests

10.2.1.3.AFP Tests

10.2.1.4.CA-19 Tests

10.2.1.5.HER2 Tests

10.2.1.6.BRCA Tests

10.2.1.7.ALK Tests

10.2.1.8.CEA Tests

10.2.1.9.EGFR Mutation Tests

10.2.1.10.KRAS Mutation Tests

10.2.1.11.Others

10.2.2.Imaging

10.2.2.1.Ultrasound

10.2.2.2.Mammography

10.2.2.3.MRI Scan

10.2.2.4.PET Scan

10.2.2.5.CT Scan

10.2.2.6.SPECT & Others

10.2.3.Biopsy

10.2.3.1.Needle Biopsy

10.2.3.2.Endoscopic Biopsy

10.2.3.3.Bone Marrow Biopsy

10.2.3.4.Others

10.2.4.Liquid Biopsy

10.2.5.Immunohistochemistry

10.2.6.In Situ Hybridization

10.3.Market Value Forecast By End User, 2016–2026

10.3.1.Hospital Associated Labs

10.3.2.Independent Diagnostic Laboratories

10.3.3.Diagnostic Imaging Centers

10.3.4.Cancer Research Institutes

10.3.5.Others

10.4.Market Value Forecast By Indication, 2016–2026

10.4.1.Breast Cancer

10.4.2.Lung Cancer

10.4.3.Colorectal Cancer

10.4.4.Melanoma

10.4.5.Blood Cancers

10.4.6.Prostate Cancer

10.4.7.Ovarian Cancer

10.4.8.Stomach Cancer

10.4.9.Liver Cancer

10.4.10.Others

10.5.Market Value Forecast By Country, 2016–2026

10.5.1.Brazil

10.5.2.Mexico

10.5.3.Rest of Latin America

10.6.Market Attractiveness Analysis 

10.6.1.By Test 

10.6.2.By End User 

10.6.3.By Indication 

10.6.4.By Country

10.7.Drivers and Restraints: Impact Analysis 

11.Western Europe Cancer Diagnostics Market Analysis and Forecast

11.1.Introduction

11.1.1.Basis Point Share (BPS) Analysis By Country

11.1.2.Y-o-Y Growth Projections By Country

11.2.Market Value Forecast By Test, 2016–2026

11.2.1.Tumor Biomarkers Tests

11.2.1.1.PSA Tests

11.2.1.2.CTC Tests

11.2.1.3.AFP Tests

11.2.1.4.CA-19 Tests

11.2.1.5.HER2 Tests

11.2.1.6.BRCA Tests

11.2.1.7.ALK Tests

11.2.1.8.CEA Tests

11.2.1.9.EGFR Mutation Tests

11.2.1.10.KRAS Mutation Tests

11.2.1.11.Others

11.2.2.Imaging

11.2.2.1.Ultrasound

11.2.2.2.Mammography

11.2.2.3.MRI Scan

11.2.2.4.PET Scan

11.2.2.5.CT Scan

11.2.2.6.SPECT & Others

11.2.3.Biopsy

11.2.3.1.Needle Biopsy

11.2.3.2.Endoscopic Biopsy

11.2.3.3.Bone Marrow Biopsy

11.2.3.4.Others

11.2.4.Liquid Biopsy

11.2.5.Immunohistochemistry

11.2.6.In Situ Hybridization

11.3.Market Value Forecast By End User, 2016–2026

11.3.1.Hospital Associated Labs

11.3.2.Independent Diagnostic Laboratories

11.3.3.Diagnostic Imaging Centers

11.3.4.Cancer Research Institutes

11.3.5.Others

11.4.Market Value Forecast By Indication, 2016–2026

11.4.1.Breast Cancer

11.4.2.Lung Cancer

11.4.3.Colorectal Cancer

11.4.4.Melanoma

11.4.5.Blood Cancers

11.4.6.Prostate Cancer

11.4.7.Ovarian Cancer

11.4.8.Stomach Cancer

11.4.9.Liver Cancer

11.4.10.Others

11.5.Market Value Forecast By Country, 2016–2026

11.5.1.Germany

11.5.2.Italy

11.5.3.France

11.5.4.U.K.

11.5.5.Spain

11.5.6.Rest of Western Europe

11.6.Market Attractiveness Analysis 

11.6.1.By Test 

11.6.2.By End User 

11.6.3.By Indication 

11.6.4.By Country

11.7.Drivers and Restraints: Impact Analysis 

12.Eastern Europe Cancer Diagnostics Market Analysis and Forecast

12.1.Introduction

12.1.1.Basis Point Share (BPS) Analysis By Country

12.1.2.Y-o-Y Growth Projections By Country

12.2.Market Value Forecast By Test, 2016–2026

12.2.1.Tumor Biomarkers Tests

12.2.1.1.PSA Tests

12.2.1.2.CTC Tests

12.2.1.3.AFP Tests

12.2.1.4.CA-19 Tests

12.2.1.5.HER2 Tests

12.2.1.6.BRCA Tests

12.2.1.7.ALK Tests

12.2.1.8.CEA Tests

12.2.1.9.EGFR Mutation Tests

12.2.1.10.KRAS Mutation Tests

12.2.1.11.Others

12.2.2. Imaging

12.2.2.1.Ultrasound

12.2.2.2.Mammography

12.2.2.3.MRI Scan

12.2.2.4.PET Scan

12.2.2.5.CT Scan

12.2.2.6.SPECT & Others

12.2.3.Biopsy

12.2.3.1.Needle Biopsy

12.2.3.2.Endoscopic Biopsy

12.2.3.3.Bone Marrow Biopsy

12.2.3.4.Others

12.2.4.Liquid Biopsy

12.2.5.Immunohistochemistry

12.2.6.In Situ Hybridization

12.3.Market Value Forecast By End User, 2016–2026

12.3.1.Hospital Associated Labs

12.3.2.Independent Diagnostic Laboratories

12.3.3.Diagnostic Imaging Centers

12.3.4.Cancer Research Institutes

12.3.5.Others

12.4.Market Value Forecast By Indication, 2016–2026

12.4.1.Breast Cancer

12.4.2.Lung Cancer

12.4.3.Colorectal Cancer

12.4.4.Melanoma

12.4.5.Blood Cancers

12.4.6.Prostate Cancer

12.4.7.Ovarian Cancer

12.4.8.Stomach Cancer

12.4.9.Liver Cancer

12.4.10.Others

12.5.Market Value Forecast By Country, 2016–2026

12.5.1.Russia

12.5.2.Poland

12.5.3.Rest of Eastern Europe

12.6.Market Attractiveness Analysis 

12.6.1.By Test 

12.6.2.By End User 

12.6.3.By Indication 

12.6.4.By Country

12.7.Drivers and Restraints: Impact Analysis 

13.APEJ Cancer Diagnostics Market Analysis and Forecast

13.1.Introduction

13.1.1.Basis Point Share (BPS) Analysis By Country

13.1.2.Y-o-Y Growth Projections By Country

13.2.Market Value Forecast By Test, 2016–2026

13.2.1.Tumor Biomarkers Tests

13.2.1.1.PSA Tests

13.2.1.2.CTC Tests

13.2.1.3.AFP Tests

13.2.1.4.CA-19 Tests

13.2.1.5.HER2 Tests

13.2.1.6.BRCA Tests

13.2.1.7.ALK Tests

13.2.1.8.CEA Tests

13.2.1.9.EGFR Mutation Tests

13.2.1.10.KRAS Mutation Tests

13.2.1.11.Others

13.2.2.Imaging

13.2.2.1.Ultrasound

13.2.2.2.Mammography

13.2.2.3.MRI Scan

13.2.2.4.PET Scan

13.2.2.5.CT Scan

13.2.2.6.SPECT & Others

13.2.3.Biopsy

13.2.3.1.Needle Biopsy

13.2.3.2.Endoscopic Biopsy

13.2.3.3.Bone Marrow Biopsy

13.2.3.4.Others

13.2.4.Liquid Biopsy

13.2.5.Immunohistochemistry

13.2.6.In Situ Hybridization

13.3.Market Value Forecast By End User, 2016–2026

13.3.1.Hospital Associated Labs

13.3.2.Independent Diagnostic Laboratories

13.3.3.Diagnostic Imaging Centers

13.3.4.Cancer Research Institutes

13.3.5.Others

13.4.Market Value Forecast By Indication, 2016–2026

13.4.1.Breast Cancer

13.4.2.Lung Cancer

13.4.3.Colorectal Cancer

13.4.4.Melanoma

13.4.5.Blood Cancers

13.4.6.Prostate Cancer

13.4.7.Ovarian Cancer

13.4.8.Stomach Cancer

13.4.9.Liver Cancer

13.4.10.Others

13.5.Market Value Forecast By Country, 2016–2026

13.5.1.China

13.5.2.India

13.5.3.Australia and New Zealand

13.5.4.ASEAN

13.5.5.Rest of APEJ

13.6.Market Attractiveness Analysis 

13.6.1.By Test 

13.6.2.By End User 

13.6.3.By Indication 

13.6.4.By Country

13.7.Drivers and Restraints: Impact Analysis 

14.Japan Cancer Diagnostics Market Analysis and Forecast

14.1.Introduction

14.1.1.Basis Point Share (BPS) Analysis By Country

14.1.2.Y-o-Y Growth Projections By Country

14.2.Market Value Forecast By Test, 2016–2026

14.2.1.Tumor Biomarkers Tests

14.2.1.1.PSA Tests

14.2.1.2.CTC Tests

14.2.1.3.AFP Tests

14.2.1.4.CA-19 Tests

14.2.1.5.HER2 Tests

14.2.1.6.BRCA Tests

14.2.1.7.ALK Tests

14.2.1.8.CEA Tests

14.2.1.9.EGFR Mutation Tests

14.2.1.10.KRAS Mutation Tests

14.2.1.11.Others

14.2.2.Imaging

14.2.2.1.Ultrasound

14.2.2.2.Mammography

14.2.2.3.MRI Scan

14.2.2.4.PET Scan

14.2.2.5.CT Scan

14.2.2.6.SPECT & Others

14.2.3.Biopsy

14.2.3.1.Needle Biopsy

14.2.3.2.Endoscopic Biopsy

14.2.3.3.Bone Marrow Biopsy

14.2.3.4.Others

14.2.4.Liquid Biopsy

14.2.5.Immunohistochemistry

14.2.6.In Situ Hybridization

14.3.Market Value Forecast By End User, 2016–2026

14.3.1.Hospital Associated Labs

14.3.2.Independent Diagnostic Laboratories

14.3.3.Diagnostic Imaging Centers

14.3.4.Cancer Research Institutes

14.3.5.Others

14.4.Market Value Forecast By Indication, 2016–2026

14.4.1.Breast Cancer

14.4.2.Lung Cancer

14.4.3.Colorectal Cancer

14.4.4.Melanoma

14.4.5.Blood Cancers

14.4.6.Prostate Cancer

14.4.7.Ovarian Cancer

14.4.8.Stomach Cancer

14.4.9.Liver Cancer

14.4.10.Others

14.5.Market Attractiveness Analysis 

14.5.1.By Test 

14.5.2.By End User 

14.5.3. By Indication 

14.6.Drivers and Restraints: Impact Analysis 

15.MEA Cancer Diagnostics Market Analysis and Forecast

15.1.Introduction

15.1.1.Basis Point Share (BPS) Analysis By Country

15.1.2.Y-o-Y Growth Projections By Country

15.2.Market Value Forecast By Test, 2016–2026

15.2.1.Tumor Biomarkers Tests

15.2.1.1.PSA Tests

15.2.1.2.CTC Tests

15.2.1.3.AFP Tests

15.2.1.4.CA-19 Tests

15.2.1.5.HER2 Tests

15.2.1.6.BRCA Tests

15.2.1.7.ALK Tests

15.2.1.8.CEA Tests

15.2.1.9.EGFR Mutation Tests

15.2.1.10.KRAS Mutation Tests

15.2.1.11.Others

15.2.2.Imaging

15.2.2.1.Ultrasound

15.2.2.2.Mammography

15.2.2.3.MRI Scan

15.2.2.4.PET Scan

15.2.2.5.CT Scan

15.2.2.6.SPECT & Others

15.2.3.Biopsy

15.2.3.1.Needle Biopsy

15.2.3.2.Endoscopic Biopsy

15.2.3.3.Bone Marrow Biopsy

15.2.3.4.Others

15.2.4.Liquid Biopsy

15.2.5.Immunohistochemistry

15.2.6.In Situ Hybridization

15.3.Market Value Forecast By End User, 2016–2026

15.3.1.Hospital Associated Labs

15.3.2.Independent Diagnostic Laboratories

15.3.3.Diagnostic Imaging Centers

15.3.4.Cancer Research Institutes

15.3.5. Others

15.4.Market Value Forecast By Indication, 2016–2026

15.4.1.Breast Cancer

15.4.2.Lung Cancer

15.4.3.Colorectal Cancer

15.4.4.Melanoma

15.4.5.Blood Cancers

15.4.6.Prostate Cancer

15.4.7.Ovarian Cancer

15.4.8.Stomach Cancer

15.4.9.Liver Cancer

15.4.10.Others

15.5.Market Value Forecast By Country, 2016–2026

15.5.1.CGG Countries

15.5.2.South Africa

15.5.3.Rest of MEA

15.6.Market Attractiveness Analysis 

15.6.1.By Test 

15.6.2.By End User 

15.6.3.By Indication 

15.6.4.By Country

15.7.Drivers and Restraints: Impact Analysis 

16.Competition Landscape

16.1.Competition Dashboard

16.2.Market Share Analysis By Company (2015)

16.3.Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)

16.3.1.Abbott Laboratories

16.3.2.F. Hoffmann-La Roche Ltd. 

16.3.3.Thermo Fisher Scientific Inc. 

16.3.4.Thermo Fisher Scientific Inc. 

16.3.5.Siemens AG 

16.3.6.Bio Rad Laboratories Inc. 

16.3.7.GE Healthcare  

16.3.8.Illumina, Inc. 

16.3.9.Koninklijke Philips N.V. 

16.3.10.Toshiba Medical Systems Corporation 

16.3.11.Agilent Technologies, Inc. 

17.Assumptions and Acronyms Used

18.Research Methodology

List of Tables

Table 1: Global Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 2: Global Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 3: Global Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015 – 2026

Table 4: Global Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

Table 5: Global Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Region, 2015 – 2026

Table 6: North America Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 7: North America Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 8: North America Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 9: North America Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015 – 2026

Table 10: North America Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

Table 11: Latin America Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 12: Latin America Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 13: Latin America Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 14: Latin America Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015 – 2026

Table 15: Latin America Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

Table 16: Western Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 17: Western Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 18: Western Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 19: Western Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015 – 2026

Table 20: Western Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

Table 21: Eastern Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 22: Eastern Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 23: Eastern Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 24: Eastern Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015 – 2026

Table 25: Eastern Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

Table 26: APEJ Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 27: APEJ Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 28: APEJ Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 29: APEJ Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015 – 2026

Table 30: APEJ Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

Table 31: Japan Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 32: Japan Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 33: Japan Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015 – 2026

Table 34: Japan Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

Table 35: MEA Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 36: MEA Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 37: MEA Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 38: MEA Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015 – 2026

Table 39: MEA Cancer Diagnostics Market Value (US$ Mn) Analysis and Forecast By End User, 2015 – 2026

List of Figures

Figure 1: Global Cancer Diagnostics Market Value Analysis and Forecast, 2015–2026 (US$ Mn)

Figure 2: Global Cancer Diagnostics Market Share Analysis (%) By Test Type, 2016 & 2026

Figure 3: Global Cancer Diagnostics Market Y-o-Y Growth (%) By Test Type, 2016–2026

Figure 4: Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Tumor Biomarker Tests, 2015 – 2026

Figure 5: Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) Imaging Tests, 2015 – 2026

Figure 6: Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Liquid Biopsy, 2015 – 2026

Figure 7: Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) Biopsy/Tissue Diagnostics Tests, 2015 – 2026

Figure 8: Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) Immunohistochemistry Tests, 2015 – 2026

Figure 9: Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) In Situ Hybridization, 2015 – 2026

Figure 10: Global Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2016–2026

Figure 11: Global Cancer Diagnostics Market Share Analysis (%) By Indication, 2016 & 2026

Figure 12: Global Cancer Diagnostics Market Y-o-Y Growth (%) By Indication, 2016–2026

Figure 13: Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Breast Cancer, 2015 – 2026

Figure 14: Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) Lung Cancer, 2015 – 2026

Figure 15: Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Colorectal Cancer, 2015 – 2026

Figure 16: Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) Melanoma, 2015 – 2026

Figure 17: Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Blood Cancer, 2015 – 2026

Figure 18: Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) Prostate Cancer, 2015 – 2026

Figure 19: Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Ovarian Cancer, 2015 – 2026

Figure 20: Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) Stomach Cancer, 2015 – 2026

Figure 21: Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Liver Cancer, 2015 – 2026

Figure 22: Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Other Indications, 2015 – 2026

Figure 23: Global Cancer Diagnostics Market Attractiveness Analysis By Indication, 2016–2026

Figure 24: Global Cancer Diagnostics Market Share Analysis (%) By End User, 2016–2026

Figure 25: Global Cancer Diagnostics Market Y-o-Y Growth (%) By End User, 2015–2026

Figure 26: Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Hospital Associated Labs, 2015 – 2026

Figure 27: Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Independent Diagnostic Laboratories, 2015 – 2026

Figure 28: Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Diagnostic Imaging Centers, 2015 – 2026

Figure 29: Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Cancer Research Institutes, 2015 – 2026

Figure 30: Global Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn) By Others, 2015 – 2026

Figure 31: Global Cancer Diagnostics Market Attractiveness Analysis By End User, 2016–2026

Figure 32: Global Cancer Diagnostics Market Share Analysis (%) By Region, 2016 & 2026

Figure 33: Global Cancer Diagnostics Market Y-o-Y Growth (%) By Region, 2015–2026

Figure 34: North America Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 35: Latin America Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 36: Western Europe Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 37: Eastern Europe Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 38: APEJ Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 39: Japan Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 40: MEA Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 41: Global Cancer Diagnostics Market Attractiveness Analysis By Region, 2016–2026

Figure 42: North America Cancer Diagnostics Market Share Analysis (%) By Country, 2016, 2026

Figure 43: North America Cancer Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026

Figure 44: U.S. Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 45: Canada Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 46: North America Cancer Diagnostics Market Attractiveness Analysis By Country, 2016 – 2026

Figure 47: North America Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026

Figure 48: North America Cancer Diagnostics Market Attractiveness Analysis By Indication, 2016 – 2026

Figure 49: North America Cancer Diagnostics Market Attractiveness Analysis By End User, 2016 – 2026

Figure 50: Latin America Cancer Diagnostics Market Share Analysis (%) By Country, 2016 & 2026

Figure 51: Latin America Cancer Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026

Figure 52: Brazil Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 53: Mexico Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 54: Rest of Latin America Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 55: Latin America Cancer Diagnostics Market Attractiveness Analysis By Country, 2016 – 2026

Figure 56: Latin America Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026

Figure 57: Latin America Cancer Diagnostics Market Attractiveness Analysis By Indication, 2016 – 2026

Figure 58: Latin America Cancer Diagnostics Market Attractiveness Analysis By End User, 2016 – 2026

Figure 59: Western Europe Cancer Diagnostics Market Share Analysis (%) By Country, 2016 & 2026

Figure 60: Western Europe Cancer Diagnostics Market

Figure 61: Germany Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 62: Italy Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 63: France Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 64: U.K. Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 65: Spain Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 66: Rest Of Western Europe Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 67: Western Europe Cancer Diagnostics Market Attractiveness Analysis By Country, 2016 – 2026

Figure 68: Western Europe Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026

Figure 69: Western Europe Cancer Diagnostics Market Attractiveness Analysis By Indication, 2016 – 2026

Figure 70: Western Europe Cancer Diagnostics Market Attractiveness Analysis By End User, 2016 – 2026

Figure 71: Eastern Europe Cancer Diagnostics Market Share Analysis (%) By Country, 2016 & 2026

Figure 72: Eastern Europe Cancer Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026

Figure 73: Poland Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 74: Russia Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 75: Rest of Eastern Europe Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 76: Eastern Europe Cancer Diagnostics Market Attractiveness Analysis By Country, 2016 – 2026

Figure 77: Eastern Europe Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026

Figure 78: Eastern Europe Cancer Diagnostics Market Attractiveness Analysis By Indication, 2016 – 2026

Figure 79: Eastern Europe Cancer Diagnostics Market Attractiveness Analysis By End User, 2016 – 2026

Figure 80: APEJ Cancer Diagnostics Market Share Analysis (%) By Country, 2016 & 2026

Figure 81: APEJ Cancer Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026

Figure 82: China Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 83: India Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 84: ASEAN Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 85: Australia and New Zealand Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 86: Rest of APEJ Europe Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 87: APEJ Cancer Diagnostics Market Attractiveness Analysis By Country, 2016 – 2026

Figure 88: APEJ Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026

Figure 89: APEJ Cancer Diagnostics Market Attractiveness Analysis By Indication, 2016 – 2026

Figure 90: APEJ Cancer Diagnostics Market Attractiveness Analysis By End User, 2016 – 2026

Figure 91: Japan Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026

Figure 92: Japan Cancer Diagnostics Market Attractiveness Analysis By Indication 2016 – 2026

Figure 93: Japan Cancer Diagnostics Market Attractiveness Analysis By End User 2016 – 2026

Figure 94: MEA Cancer Diagnostics Market Share Analysis (%) By Country, 2016, 2026

Figure 95: MEA Cancer Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026

Figure 96: GCC Countries Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 97: South Africa Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 98: Rest of MEA Europe Cancer Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 99: MEA Cancer Diagnostics Market Attractiveness Analysis By Country, 2016 – 2026

Figure 100: MEA Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026

Figure 101: MEA Cancer Diagnostics Market Attractiveness Analysis By Indication, 2016 – 2026

Figure 102: MEA Cancer Diagnostics Market Attractiveness Analysis By End User, 2016 – 2026